At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
In Brief
A Phase 3 clinical trial evaluating total-body irradiation, allogeneic hematopoietic stem cell transplantation, and 15 other interventions for Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome and 18 related conditions. Completed, enrolled 25 participants across 8 sites in 2 countries.
Detailed Summary
RATIONALE: Giving chemotherapy, such as fludarabine phosphate, busulfan, and cyclophosphamide, and total-body radiation therapy before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not yet known whether low-dose chemotherapy and total-body radiation therapy is more effective than high-dose chemotherapy in treating patients with myelodysplastic syndrome or acute myeloid leukemia. PURPOSE: This phase III trial is studying low-dose conditioning to see how well it works compared to high-dose conditioning followed by peripheral blood stem cell transplant in treating patients with myelodysplastic syndromes or acute myeloid leukemia
Study Details
Timeline
Interventions
Radiation
Undergo allogeneic transplantation
Given IV
Given orally
Given IV or orally
Given IV or orally
Given IV
Undergo transplantation
Undergo allogeneic transplantation
Correlative studies
Correlative studies
Correlative studies
Correlative studies
Correlative studies
Correlative studies
Given IV or orally
Given IV